+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oligonucleotide Synthesis Market - Global Forecast 2026-2032- Product Image
Oligonucleotide Synthesis Market - Global Forecast 2026-2032- Product Image
Sale

Oligonucleotide Synthesis Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337611
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oligonucleotide Synthesis Market is projected to reach USD 12.02 Billion in 2026. It is expected to continue growing at a CAGR of 17.43%, reaching USD 31.69 Billion by 2032.

Oligonucleotide synthesis is a core enabling technology for precision medicine, molecular diagnostics, synthetic biology, and genomic research. The field covers custom DNA and RNA oligos, antisense oligonucleotides, siRNA, aptamers, CRISPR guide RNAs, primers, probes, and modified nucleic acids produced primarily through solid-phase phosphoramidite chemistry.

Demand is supported by FDA-cleared molecular tests, expanding genomic sequencing workflows, and approved RNA-targeted therapies such as nusinersen, patisiran, givosiran, inclisiran, and tofersen. As therapeutic pipelines mature, buyers increasingly evaluate oligonucleotide synthesis providers on GMP capacity, analytical quality, modification breadth, delivery expertise, regulatory documentation, and supply-chain reliability.

Transformative Shifts in the Oligonucleotide Landscape

The oligonucleotide synthesis landscape is shifting from research-scale custom orders toward clinical and commercial manufacturing. Therapeutic oligos require stringent control of sequence fidelity, impurity profiles, endotoxin, residual solvents, and identity testing by methods such as LC-MS, HPLC, capillary electrophoresis, and NMR.

Manufacturers are investing in higher-throughput synthesizers, greener solvent strategies, automation, closed processing, and integrated CDMO services. At the same time, demand for complex chemistries, including 2'-O-methyl, 2'-MOE, phosphorothioate backbones, LNA, GalNAc conjugates, and chemically modified siRNA, is raising technical requirements and quality expectations across the value chain.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is improving oligonucleotide discovery and manufacturing by accelerating sequence selection, off-target screening, secondary-structure prediction, immunogenicity assessment, and manufacturability evaluation. AI-enabled models are increasingly used with public genomic databases, RNA expression datasets, and high-throughput screening outputs to prioritize candidates before costly wet-lab validation.

In production, machine learning can support real-time process monitoring, predictive maintenance, chromatographic method development, and deviation detection. The strongest near-term value is not replacing validated chemistry, but reducing cycle times, improving batch consistency, strengthening quality-by-design workflows, and helping quality teams interpret complex analytical datasets.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is gaining importance as China, India, Japan, South Korea, and Australia expand genomics, vaccine, and biopharmaceutical capacity. China offers scale, domestic biotech demand, and active nucleic acid research; India contributes cost-competitive manufacturing, clinical research services, and expanding diagnostics infrastructure; Japan maintains advanced nucleic acid science and high-quality pharmaceutical standards; while South Korea and Australia support translational medicine, clinical studies, and public-health genomics ecosystems.

North America remains a leading innovation center because of U.S. FDA experience with RNA-targeted drugs, NIH-funded genomics research, venture-backed biotechnology clusters, and established GMP CDMO infrastructure, with Canada contributing genomics, academic medicine, and clinical translation. Europe is strong in regulatory science, academic translation, and quality manufacturing, supported by EMA oversight and coordinated research programs. Latin America is developing demand through molecular diagnostics, infectious-disease surveillance, and clinical research activity, led by Brazil and Mexico. The Middle East is advancing national genomics, precision medicine, and hospital-based sequencing programs, particularly in Gulf states. Africa is building capacity through public-health sequencing, pathogen surveillance, newborn screening initiatives, and regional laboratory networks, creating a foundation for future oligonucleotide demand.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN demand is led by Singapore’s biomedical hub and growing diagnostics adoption across Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where infectious-disease testing, academic genomics, and clinical research are increasing the need for primers, probes, and sequencing reagents. The GCC is advancing national genomics and precision medicine programs in Saudi Arabia, the United Arab Emirates, Qatar, and neighboring states, supporting demand for sequencing reagents, synthetic oligos, probes, and clinical research tools.

The European Union benefits from harmonized pharmaceutical regulation, Horizon Europe research funding, cross-border health-data initiatives, and strong GMP expectations. BRICS economies provide population scale, manufacturing depth, expanding healthcare access, and growing biotechnology capabilities, with China and India particularly relevant to oligonucleotide production and research supply chains. G7 countries concentrate advanced therapeutic development, regulatory maturity, public biomedical funding, and early adoption of RNA-targeted medicines. NATO members increasingly view biosecurity, resilient supply chains, pathogen surveillance, and dual-use biotechnology governance as strategic priorities, reinforcing the importance of secure oligonucleotide sourcing and quality-controlled nucleic acid manufacturing.

Key Country Insights Across Major Oligonucleotide Markets

The United States leads therapeutic oligonucleotide commercialization through FDA approvals, biotech financing, academic research, and specialized GMP manufacturing, while Canada contributes genomics research, hospital-based innovation, and clinical translation. Mexico and Brazil represent important Latin American demand centers for molecular diagnostics, public-health laboratories, infectious-disease surveillance, and contract research, with Brazil also supported by a large academic and biomedical research base.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong academic science, hospital research networks, clinical trial infrastructure, and regulated biomanufacturing, with Germany and France maintaining deep pharmaceutical and analytical capabilities and the United Kingdom supporting genomics-driven clinical adoption. Russia maintains domestic life-science and pharmaceutical capabilities under constrained international supply conditions, increasing emphasis on localized sourcing and research continuity. In Asia-Pacific, China, India, Japan, Australia, and South Korea are critical markets: China and India are scaling production, research services, and diagnostics capacity; Japan emphasizes innovation, quality, and advanced nucleic acid science; South Korea is expanding biopharmaceutical manufacturing and translational medicine; and Australia supports clinical research, population genomics, and public-health sequencing programs.

Actionable Recommendations for Industry Leaders

Industry leaders should align capacity with the shift from discovery oligos to GMP therapeutic production. Priority investments include validated solid-phase synthesis platforms, high-resolution purification, mass spectrometry, impurity characterization, electronic batch records, data integrity controls, and robust supplier qualification for amidites, controlled-pore glass, enzymes, solvents, and specialty reagents.

Commercial teams should segment customers by research, diagnostic, and therapeutic use cases. Winning providers will combine rapid custom synthesis, regulatory documentation, scalable tech transfer, secure data handling, and expertise in modified RNA, antisense chemistry, siRNA, CRISPR guide RNA, aptamers, probes, and conjugation technologies. Leaders should also strengthen regional redundancy, establish quality agreements early, and integrate AI-enabled design tools with validated laboratory workflows.

Research Methodology

This executive summary is based on secondary research from regulatory databases, peer-reviewed literature, clinical trial registries, government research programs, pharmacopeial references, and recognized industry standards for pharmaceutical quality systems. Insights were cross-checked against known FDA and EMA precedents for oligonucleotide therapeutics, documented genomics initiatives, and established nucleic acid analytical practices.

The analysis evaluates technology drivers, manufacturing shifts, regional adoption patterns, regulatory considerations, and competitive priorities. It emphasizes verifiable evidence, including approved therapeutic modalities, public biomedical programs, validated chemistry platforms, and documented quality requirements, while avoiding unsupported projections, vendor claims, market estimation, market sizing, market share, or forecasting.

Conclusion

Oligonucleotide synthesis is moving from a specialized research service into a strategic manufacturing platform for precision therapeutics, molecular diagnostics, and genomic innovation. Scientific validation from approved RNA-targeted medicines has strengthened confidence in antisense, siRNA, and other nucleic acid modalities, while molecular testing and sequencing workflows continue to expand practical use cases.

Future competitiveness will depend on quality systems, manufacturing scale, chemistry expertise, data-driven development, regulatory readiness, and regional supply resilience. Organizations that integrate AI-enabled design, GMP readiness, analytical rigor, secure data practices, and customer-specific technical support will be best positioned to meet the evolving requirements of oligonucleotide synthesis.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oligonucleotide Synthesis Market, by Product Type
7.1. Introduction
7.2. Equipment/Instruments
7.2.1. DNA/RNA Synthesizers
7.2.2. Microarray Synthesizers
7.3. Reagents & Consumables
7.3.1. Enzymes
7.3.2. Labeling Reagents
7.3.3. Purification Reagents
7.3.4. Synthesis Reagents
7.4. Software & Services
7.4.1. Bioinformatics Tools
7.4.2. Cloud Storage & Management Solution
7.4.3. Custom Oligo Synthesis Services
7.4.4. Data Analysis Platforms
7.5. Synthesized Oligonucleotides
7.5.1. DNA Oligonucleotides
7.5.2. RNA Oligonucleotides
8. Oligonucleotide Synthesis Market, by Synthesis Scale
8.1. Introduction
8.2. Custom Oligonucleotide Synthesis
8.3. Large-Scale/Commercial Manufacturing
9. Oligonucleotide Synthesis Market, by Delivery Method
9.1. Introduction
9.2. Enzymatic Synthesis
9.3. Solid-Phase Synthesis
10. Oligonucleotide Synthesis Market, by Application
10.1. Introduction
10.2. Diagnostics
10.2.1. Biosensors
10.2.2. Molecular Imaging
10.2.3. PCR & Sequencing
10.3. Drug Discovery & Development
10.3.1. Lead Optimization
10.3.2. Target Validation
10.4. Research
10.4.1. Functional Genomics
10.4.2. Gene Expression Analysis
10.4.3. Gene Synthesis
10.5. Therapeutics
10.5.1. Antisense Therapy
10.5.2. CRISPR-Based Therapeutics
10.5.3. RNA Interference
11. Oligonucleotide Synthesis Market, by End-User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Contract Research Organizations
11.4. Diagnostic Laboratories
11.5. Pharmaceutical & Biotechnology Companies
12. Oligonucleotide Synthesis Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Oligonucleotide Synthesis Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Oligonucleotide Synthesis Market, by Country
14.1. United States
14.2. Germany
14.3. China
14.4. United Kingdom
14.5. India
14.6. Japan
14.7. Russia
14.8. Brazil
14.9. Canada
14.10. Italy
14.11. Mexico
14.12. France
14.13. Spain
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Agilent Technologies, Inc.
16.2. Ajinomoto Bio-Pharma Services
16.3. Bio-synthesis Inc.
16.4. Biocomma Ltd.
16.5. Biolegio B.V.
16.6. Biolytic Lab Performance Inc.
16.7. Bon Opus Biosciences, LLC
16.8. Creative Biogene
16.9. Cusabio Technology LLC
16.10. Danaher Corporation
16.11. Eurofins Genomics LLC
16.12. Eurogentec S.A. by Kaneka Corporation
16.13. GE HealthCare Technologies Inc.
16.14. Generi Biotech
16.15. Genscript Corporation
16.16. Hongene Biotech Corp.
16.17. LGC Genomics Limited
16.18. Maravai Intermediate Holdings, LLC
16.19. Merck KGaA
16.20. Microsynth AG
16.21. Nitto Denko Avecia Inc.
16.22. Novartis AG
16.23. PerkinElmer, Inc.
16.24. REPROCELL Inc.
16.25. Synbio Technologies
16.26. TAG Copenhagen A/S
16.27. TCI Chemicals Pvt. Ltd.
16.28. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL EQUIPMENT/INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL EQUIPMENT/INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL EQUIPMENT/INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DNA/RNA SYNTHESIZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DNA/RNA SYNTHESIZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DNA/RNA SYNTHESIZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MICROARRAY SYNTHESIZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MICROARRAY SYNTHESIZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MICROARRAY SYNTHESIZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL LABELING REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LABELING REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LABELING REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PURIFICATION REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PURIFICATION REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PURIFICATION REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SYNTHESIS REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SYNTHESIS REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SYNTHESIS REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BIOINFORMATICS TOOLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL BIOINFORMATICS TOOLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL BIOINFORMATICS TOOLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CLOUD STORAGE & MANAGEMENT SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CLOUD STORAGE & MANAGEMENT SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CLOUD STORAGE & MANAGEMENT SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CUSTOM OLIGO SYNTHESIS SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CUSTOM OLIGO SYNTHESIS SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CUSTOM OLIGO SYNTHESIS SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DNA OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DNA OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DNA OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL RNA OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RNA OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL RNA OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CUSTOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CUSTOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CUSTOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL LARGE-SCALE/COMMERCIAL MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL LARGE-SCALE/COMMERCIAL MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL LARGE-SCALE/COMMERCIAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ENZYMATIC SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ENZYMATIC SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ENZYMATIC SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SOLID-PHASE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SOLID-PHASE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SOLID-PHASE SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL BIOSENSORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BIOSENSORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BIOSENSORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MOLECULAR IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL MOLECULAR IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MOLECULAR IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PCR & SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PCR & SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PCR & SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TARGET VALIDATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TARGET VALIDATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ANTISENSE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ANTISENSE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ANTISENSE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL CRISPR-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CRISPR-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL CRISPR-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL RNA INTERFERENCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL RNA INTERFERENCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL RNA INTERFERENCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 168. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 170. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 171. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 172. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 173. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 174. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 175. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 176. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 177. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 178. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 179. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 180. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 181. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 196. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 198. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 199. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 200. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 201. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 202. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 203. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 204. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 205. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 206. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 207. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 208. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 209. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 210. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 213. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 214. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 215. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 216. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 217. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 218. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 219. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 221. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 222. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 223. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 224. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 225. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 227. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 228. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 229. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 230. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 231. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 232. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 233. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 234. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 235. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 236. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 237. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 238. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 253. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 254. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 255. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 256. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 257. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 258. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 259. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 260. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 261. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 263. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 264. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 265. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 266. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 267. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 268. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 269. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 270. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 271. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 272. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 273. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 274. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 275. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 276. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 277. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 278. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 279. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 280. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 281. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 282. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 283. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 284. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 285. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 286. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 287. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 288. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 289. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 290. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 291. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 292. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 293. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 294. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 295. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 304. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 305. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 306. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 307. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 308. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 309. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 310. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 311. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 312. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 313. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 314. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 315. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 316. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 317. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 318. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 319. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 320. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 321. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 322. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 323. GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 324. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 326. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 327. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 328. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 329. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2017-2032 (USD MILLION)
TABLE 330. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2017-2032 (USD MILLION)
TABLE 331. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 332. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 333. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 334. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 335. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 336. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 337. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZ

Companies Mentioned

  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Bio-synthesis Inc.
  • Biocomma Ltd.
  • Biolegio B.V.
  • Biolytic Lab Performance Inc.
  • Bon Opus Biosciences, LLC
  • Creative Biogene
  • Cusabio Technology LLC
  • Danaher Corporation
  • Eurofins Genomics LLC
  • Eurogentec S.A. by Kaneka Corporation
  • GE HealthCare Technologies Inc.
  • Generi Biotech
  • Genscript Corporation
  • Hongene Biotech Corp.
  • LGC Genomics Limited
  • Maravai Intermediate Holdings, LLC
  • Merck KGaA
  • Microsynth AG
  • Nitto Denko Avecia Inc.
  • Novartis AG
  • PerkinElmer, Inc.
  • REPROCELL Inc.
  • Synbio Technologies
  • TAG Copenhagen A/S
  • TCI Chemicals Pvt. Ltd.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 12.02 Billion
Forecasted Market Value ( USD ) by 2032 $ 31.69 Billion
Compound Annual Growth Rate17.4%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

High-throughput Oligonucleotide Synthesizers Market - Global Forecast 2026-2032 - Product Image

High-throughput Oligonucleotide Synthesizers Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Oligonucleotide Therapeutics Market - Global Forecast 2026-2032 - Product Image

Oligonucleotide Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Oligonucleotide Synthesis - Global Strategic Business Report - Product Image

Oligonucleotide Synthesis - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Oligonucleotide Synthesis Market Report by Product, Application, End Use, and Region 2026-2034 - Product Image

Oligonucleotide Synthesis Market Report by Product, Application, End Use, and Region 2026-2034

  • Report
  • 147 Pages
  • Global
From
Oligonucleotide Synthesis Reagents Market Size, Share & Trends Analysis Report by Product, Application, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Oligonucleotide Synthesis Reagents Market Size, Share & Trends Analysis Report by Product, Application, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.